Page 19 - hypertension_newsletter7

REFLECTIONS
Hypertension
Hypertension Global Newsletter #7 2024

11. A higher adherence to perindopril-based anti-hypertensive therapy is associated with a reduced risk of
cardiovascular outcomes and all-cause mortality in real clinical practice in Italy. Masi S, et al. Eur Heart J. Hypertension
2024;45(Suppl 1): ehae666.2587.

SECONDARY AND RESISTANT HYPERTENSION

12. Semaglutide for the treatment of resistant hypertension. Kennedy C, et al. Eur Heart J. 2024;45(Suppl 1):
ehae666.2590.

13. 10 years after treatment with renal denervation of the sympathetic nerves for resistant hypertension: What
happened to the patients and their office blood pressure? An observational study. Melchior T, et al. Eur Heart J.
2024;45(Suppl 1): ehae666.2597.

ESC 2024 – HOT LINE

14. The BedMed and BedMed-Frail randomised controlled trials - Effect of antihypertensive timing on mortality
and morbidity. Garrison S, Congress Presentation; (requires sign-in to access) https://esc365.escardio.org/
presentation/290223] Press release: https://www.escardio.org/The-ESC/Press-Office/Press-releases/Evening-vs-morning-
dosing-of-blood-pressure-medication-no-differences-seen
15. GMRx2 - Efficacy and safety of a novel triple single pill combination. Rodgers A, Congress Presentation; (requires
sign-in to access) https://esc365.escardio.org/presentation/290229 Press release: https://www.escardio.org/The-ESC/
Press-Office/Press-releases/Novel-low-dose-triple-single-pill-combination-shows-efficacy-and-tolerability-in-two-
international-trials

16. QUADRO - A single 4-drug combination in hypertension. Taddei S, Congress Presentation (requires sign-in to access);
https://esc365.escardio.org/presentation/290232] Press release: https://www.escardio.org/The-ESC/Press-Office/Press-
releases/A-single-tablet-with-4-blood-pressure-lowering-drugs-can-be-more-effective-than-taking-3-drugs-in-separate-pills

ACRONYMS:
ABPM, ambulatory blood pressure monitoring; ACEi, angiotensin-converting enzyme inhibitor; AEs, adverse events; AHA, American
Heart Association; ANCOVA, analysis of covariance; AOMs, antiobesity medications; ARBs, angiotensin receptor blocker; BMI, body
mass index; BP, blood pressure; CAD, coronary artery disease; CCB, calcium channel blocker; CKD, chronic kidney disease; CI,
confidence interval; CV, cardiovascular; CVD, cardiovascular disease; DBP, diastolic blood pressure; ED, emergency department;
eGFR, estimated glomerular filtration rate; ESC, European Society of Cardiology; F/U, follow-up; GABA, gamma-aminobutyric acid;
GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; GLP-1 RA, glucagon-like peptide-1 receptor
agonist; HBPM, home blood pressure monitoring; HF, heart failure; HMOD, hypertension-mediated organ damage; HR, hazard ratio;
HR heart rate; HTN, hypertension; ICU, intensive care unit; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction;
NNH, number needed to harm; OH, orthostatic hypotension; POMC, proopiomelanocortin; RCTs, randomised controlled trials; RH,
resistant hypertension; SBP, systolic blood pressure; SCORE2, Systematic COronary Risk Evaluation 2; SCORE2-OP, Systematic
COronary Risk Evaluation 2–Older Persons; SD, standard deviation; SPC, Scientific Planning Committee; T2DM, type 2 diabetes
mellitus; TI, therapeutic inertia.

TABLE OF CONTENTS